1059 related articles for article (PubMed ID: 26070241)
1. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
2. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
Ding H; Underwood R; Lavalley N; Yacoubian TA
Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
[TBL] [Abstract][Full Text] [Related]
4. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
8. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
[TBL] [Abstract][Full Text] [Related]
10. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.
Sterky FH; Hoffman AF; Milenkovic D; Bao B; Paganelli A; Edgar D; Wibom R; Lupica CR; Olson L; Larsson NG
Hum Mol Genet; 2012 Mar; 21(5):1078-89. PubMed ID: 22090423
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Nishi K
Brain Res; 1997 Oct; 771(1):133-41. PubMed ID: 9383016
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
13. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
14. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
15. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
17. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
18. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]